0000000000331556

AUTHOR

Holger Lawall

showing 3 related works from this author

Baseline factors affecting closure of venous leg ulcers

2017

Objective: The objective of this study was to characterize factors associated with closure of venous leg ulcers (VLUs) in a pooled analysis of subjects from three randomized clinical trials. Methods: Closure of VLUs after treatment with HP802-247, an allogeneic living cell therapy consisting of growth-arrested human keratinocytes and fibroblasts, vs standard therapy with compression bandaging was evaluated in three phase 3 clinical trials of similar design. Two trials enrolled subjects with VLUs ranging from 2 cm2 to 12 cm2 in area with 12-week treatment periods; the third trial enrolled subjects with VLUs between >12 cm2 and #36 cm2 with a 16-week treatment period. The first trial went to …

Malemedicine.medical_specialtyCell- and Tissue-Based Therapy030204 cardiovascular system & hematologyPlaceboVaricose Ulcerlaw.invention030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled triallawCompression BandagesInternal medicineDiabetes mellitusmedicineHumansProspective StudiesClosure (psychology)Prospective cohort studyWound Healingbusiness.industryMiddle AgedPrognosismedicine.diseaseClinical trialTreatment OutcomechemistryFemaleSurgeryHuman medicineGlycated hemoglobinCardiology and Cardiovascular MedicinebusinessBody mass indexDiabetic AngiopathiesJournal of Vascular Surgery: Venous and Lymphatic Disorders
researchProduct

Periphere arterielle Verschlusskrankheit: Wann ist ein PCSK9-Inhibitor sinnvoll?

2018

ZusammenfassungDie Leitlinie der Europäischen Gesellschaft für Kardiologie empfiehlt bei Patienten mit manifester peripherer arterieller Verschlusskrankheit (PAVK) ebenso wie bei KHK oder zerebrovaskulärer Erkrankung einen LDL-C-Zielwert < 70 mg/dL oder eine Reduktion um 50 %, wenn der Ausgangswert zwischen 70 und 135 mg/dL liegt. Die Applikation eines PCSK9-Inhibitors ermöglicht die Zielwerterreichung für viele Patienten, die dies unter einer maximalen Statintherapie in Kombination mit Ezetemib nicht erreichen. In der Fourier-Studie konnte für Patienten mit PAVK, die bei Studieneinschluss weder einen Myokardinfarkt noch einen Apoplex erlitten hatten, eine deutliche Risikoreduktion (RR) …

Ldl cholesterolGynecologymedicine.medical_specialtybusiness.industryCholesterolGeneral Medicine030204 cardiovascular system & hematologyCoronary heart disease03 medical and health scienceschemistry.chemical_compound0302 clinical medicinechemistryMedicineLdl cholesterin030212 general & internal medicinebusinessPCSK9 InhibitorsDMW - Deutsche Medizinische Wochenschrift
researchProduct

The Diagnosis and Treatment of Peripheral Arterial Vascular Disease

2016

Background In peripheral arterial occlusive disease (PAOD), arterial stenosis or occlusion impairs perfusion in the territory of the distal portion of the aorta and the iliac and leg arteries. In Germany, the prevalence of PAOD rises with age, reaching 20% among persons over age 70. Methods This guideline was prepared by a collaboration of 22 medical specialty societies and two patient self-help organizations on the basis of pertinent publications that were retrieved by a systematic search in PubMed for articles that appeared from 2008 to April 2014, with a subsequent update to May 2015. Results 294 articles were assessed, including 34 systematic reviews and 98 randomized controlled trials …

Duplex ultrasonographymedicine.medical_specialtymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentPhysical examinationClinical Practice GuidelineGeneral MedicineGuideline030204 cardiovascular system & hematologyRevascularizationlaw.inventionSurgery03 medical and health sciences0302 clinical medicineBlood pressureRandomized controlled triallawArterial Occlusive DiseasesMedicine030212 general & internal medicinemedicine.symptombusinessClaudicationDeutsches Ärzteblatt international
researchProduct